ArticleDer Nervenarzt2026

[Anti-amyloid antibodies against Alzheimer's disease : Lecanemab and donanemab in practice-Clinical importance, patient selection and safety management].

Timo Jan ObersteinPubMed ↗Publisher ↗

No numbers read from the abstract.